Senseonics Holdings, Inc. (FRA:6L60)
Germany · Delayed Price · Currency is EUR | Market Cap | 506.18M +126.1% |
| Revenue (ttm) | 52.85M +104.8% |
| Net Income | -107.91M |
| EPS | -2.06 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70 |
| Open | 9.10 |
| Previous Close | 9.30 |
| Day's Range | 9.10 - 9.40 |
| 52-Week Range | 4.04 - 9.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 4, 2027 |
About Senseonics Holdings
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company ser... [Read more]
Financial Performance
In 2025, Senseonics Holdings's revenue was $35.26 million, an increase of 56.89% compared to the previous year's $22.47 million. Losses were -$69.11 million, -12.09% less than in 2024.
Financial numbers in USD Financial StatementsNews
Senseonics Holdings Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Q3 revenue grew 140% YoY to $19.6M, and 2026 revenue guidance rose to $68M-$70M. The fully implantable Freedom product is targeted for market availability by mid-2028, with profitability expected in the 2028 timeframe.
Senseonics Holdings Slides: Investor presentation
Senseonics Holdings has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
Senseonics Holdings Transcript: Stifel 2026 Healthcare Conference 2026
In-house commercial operations, DTC investment and EON access supported strong 2026 execution. Management expects continued growth and operating leverage, with Gemini targeted for 2H 2027 and Freedom for 2028.
Senseonics raises FY26 revenue view to $68M-$70M from $62M-$66M
Consensus $64.24M. Raises FY26 gross margin view to over 61% from 58%-61%. Brian Hansen, Chief Commercial Officer of Senseonics (SENS) added, “Multiple initiatives to expand awareness and access creat...
Senseonics upgraded to Market Perform from Underperform at Raymond James
Raymond James analyst Jayson Bedford upgraded Senseonics (SENS) to Market Perform from Underperform without a price target The company has made progress on its U.S. execution and capital needs, the…
Senseonics price target raised to $11 from $10 at Barclays
Barclays analyst Christopher Pasquale raised the firm’s price target on Senseonics (SENS) to $11 from $10 and keeps an Equal Weight rating on the shares. The firm reported strong Q3…
Senseonics price target raised to $10 from $9 at Stifel
Stifel analyst Jonathan Block raised the firm’s price target on Senseonics (SENS) to $10 from $9 and keeps a Hold rating on the shares.
Senseonics price target raised to $20 from $18 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Senseonics (SENS) to $20 from $18 and keeps an Outperform rating on the shares. The company reported a big beat…
Senseonics price target raised to $17 from $15 at TD Cowen
TD Cowen raised the firm’s price target on Senseonics (SENS) to $17 from $15 and keeps a Buy rating on the shares. The firm said they delivered a breakout 3Q…
Senseonics price target raised to $18.50 from $16 at Lake Street
Lake Street analyst Ben Haynor raised the firm’s price target on Senseonics (SENS) to $18.50 from $16 and keeps a Buy rating on the shares following what the firm identifies…
Senseonics Holdings Earnings Call Transcript: Q3 2026
Q3 revenue rose ~140% YoY to a record $19.6M, lifting FY 2026 guidance to $68M-$70M. Growth and margin gains accompany expanding pump partnerships and Freedom development, with management expecting 2027 revenue above $100M.
Senseonics Holdings Earnings release: Q3 2026
Senseonics Holdings released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Senseonics Holdings Quarterly report: Q3 2026
Senseonics Holdings has published its Q3 2026 quarterly earnings report on November 9, 2026.
Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results
Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million,...
Senseonics initiates first-in-human clinical study evaluating Freedom
Senseonics (SENS) announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device ...
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics' innovation roadmap, with potential launch in 2028
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continu...
Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuo...
Senseonics initiated with an Equal Weight at Barclays
Barclays initiated coverage of Senseonics (SENS) with an Equal Weight rating and $10 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
Beta Bionics to integrate iLet Bionic Pancreas, mint with Eversense 365
Beta Bionics (BBNX) announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics’ (SENS) Eversense 365 continuous glucose monitoring system...
Senseonics partners with Beta Bionics to integrate Eversense 365
Senseonics (SENS) announced a partnership with Beta Bionics (BBNX). The companies are collaborating to integrate Eversense 365 CGM with Beta Bionics’ iLet Bionic Pancreas automated insulin delivery sy...
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancre...
Senseonics To Participate in Upcoming Institutional Investor Conferences
GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continu...
Senseonics reports Q2 EPS (63c), consensus (62c)
Reports Q2 revenue $14.5M, consensus $12.91M. U.S. revenue grew more than 150% year-over-year to $12.6M. “This was the strongest quarter in Senseonics (SENS)’ history, achieving record revenue and exp...
Senseonics Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenue growth of 120% year-over-year, with U.S. revenue up 150% and gross margin reaching 59%. Full-year guidance was raised for both revenue and margin, supported by strong commercial execution, a successful European transition, and a strengthened balance sheet.